Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice would be considered clinical trial ineligible. On...

Full description

Bibliographic Details
Main Authors: Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Current Oncology
Subjects:
immunotherapy
non-small-cell lung cancer (NSCLC)
older adults
Online Access:https://www.mdpi.com/1718-7729/28/5/357

Internet

https://www.mdpi.com/1718-7729/28/5/357

Similar Items